Tumor necrosis factor alpha drives cadherin 11 expression in rheumatoid inflammation.

Arthritis Rheum. 2008 Oct;58(10):3051-62 Authors: Vandooren B, Cantaert T, ter Borg M, Noordenbos T, Kuhlman R, Gerlag D, Bongartz T, Reedquist K, Tak PP, Baeten D OBJECTIVE: Cadherin 11 expressed on fibroblast-like synoviocytes (FLS) plays a key role in normal synovial architecture. The purpose of this study was to examine the expression of cadherin 11…

Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.

Scand J Rheumatol. 2008 Nov-Dec;37(6):401-9 Authors: Bramlage CP, Kaps C, Ungethüm U, Bramlage P, Koziolek M, Wessels J, Krenn V, Pruss A, Müller GA, Strutz F, Burmester GR, Häupl T OBJECTIVE: Growth differentiation factor-5 (GDF-5), a member of the transforming growth factor (TGF)-beta family, is involved in joint development during embryogenesis and has the potential…

Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?

Rev Med Interne. 2009 Mar;30(3):287-99 Authors: Larghero J, Vija L, Lecourt S, Michel L, Verrecchia F, Farge D Mesenchymal stem cells (MSC) represent a population of the bone marrow microenvironment, which participates in the regulation of haematopoietic stem cells (HSC) self-renewal and differentiation. MSC are multipotent non-haematopoietic progenitors, which have been explored as a promising…

Mesenchymal stem cells in arthritic diseases.

Arthritis Res Ther. 2008;10(5):223 Authors: Chen FH, Tuan RS Mesenchymal stem cells (MSCs), the nonhematopoietic progenitor cells found in various adult tissues, are characterized by their ease of isolation and their rapid growth in vitro while maintaining their differentiation potential, allowing for extensive culture expansion to obtain large quantities suitable for therapeutic use. These properties…

Stem cell transplantation in rheumatoid arthritis.

Autoimmunity. 2008 Dec;41(8):625-31 Authors: Snowden JA, Kapoor S, Wilson AG The therapeutic potential of high dose cytotoxic therapy and stem cell transplantation (SCT) in severe rheumatoid arthritis (RA) was originally supported by animal studies and serendipitous clinical cases where allogeneic and autologous procedures were shown to ameliorate and potentially cure the disease. Phase I and…

The pro-inflammatory immunological memory : twist1 as a marker for chronically activated T lymphocytes

Z Rheumatol. 2008 Dec;67(8):684-8 Authors: Albrecht I, Niesner U, Janke M, Radbruch A, Chang H State-of-the-art immunosuppressive therapies, though efficient in the treatment of rheumatic inflammatory disorders, in most cases do not provide a cure. Complete immunablation and the associated deletion of the reactive immunological memory followed by reconstitution of the “healthy” immune system from…

Current value of stem-cell transplantation in autoimmune diseases

Z Rheumatol. 2008 Dec;67(8):716-22 Authors: Kötter I, Schmalzing M, Henes J, Vogel W, Kanz L Transplantations of autologous or allogeneic stem cells from bone marrow or peripheral blood are preformed for the treatment of resistant autoimmune diseases. Data have been systematically collected since 1996. We describe the historical development of this procedure for autoimmune diseases,…

Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.

Arthritis Rheum. 2008 Dec;58(12):3765-75 Authors: Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE OBJECTIVE: To evaluate the ability of SNX-7081, a novel small molecule inhibitor of Hsp90, to block components of inflammation, including cytokine production, protein kinase activity, and…